Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9829849 | 0.90 | CLEC4M (0.56) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL7291947 | 0.88 | CLEC4M (0.54) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL13265532 | 0.88 | CLEC4M (0.54) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL12693514 | 0.86 | CLEC4M (0.53) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL61146 | 0.85 | CLEC4M (0.52) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL50925 | 0.85 | KDM4E (0.58) | KDM4EMAPTCYP1A2CNR1CNR2 | |
| SCHEMBL7291746 | 0.81 | CLEC4M (0.51) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL7291074 | 0.81 | CLEC4M (0.50) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL397393 | 0.81 | CLEC4M (0.52) | CLEC4MMEN1KMT2AKDM4EMAPT | |
| SCHEMBL14845114 | 0.79 | CLEC4M (0.63) | CLEC4MMEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8129382-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129382-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7750008-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750008-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-12-03 | — | — | US | disclosed |
| US-7601719-B2 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601719-B2 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | MGI GP, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | MGI GP, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2004105700-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | GUILDFORD PHARMACEUTICALS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | PARP1, PARP2, NLRP3 | CLEC4M 3359/4885MEN1 4831/4885KMT2A 2073/4885 |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | CLEC4M 3564/4885MEN1 3554/4885KMT2A 1388/4885 |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | PARP1, PARP2, PARP11 | CLEC4M 2758/4885MEN1 348/4885KMT2A 209/4885 |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | CLEC4M 3564/4885MEN1 3554/4885KMT2A 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.